<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypertrophic cardiomyopathy: Management of patients without outflow tract obstruction</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypertrophic cardiomyopathy: Management of patients without outflow tract obstruction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypertrophic cardiomyopathy: Management of patients without outflow tract obstruction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Maron, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J McKenna, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypertrophic cardiomyopathy (HCM) is a genetically determined cardiomyopathy that typically manifests as left ventricular hypertrophy (LVH). LVH results in structural and functional abnormalities that can produce a variety of symptoms that include dyspnea, chest discomfort, palpitations, and syncope.</p><p>The treatment of patients with HCM who do not have left ventricular outflow tract (LVOT) obstruction will be reviewed here.</p><p>The approach to identifying left ventricular outflow tract obstruction is reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation"</a>.)</p><p>The treatment of patients with LVOT obstruction can be found separately. (See  <a class="medical medical_review" href="/d/html/4920.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients with outflow tract obstruction"</a>.)</p><p>The management of other aspects of HCM can be found elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4926.html" rel="external">"Hypertrophic cardiomyopathy in adults: Supraventricular tachycardias including atrial fibrillation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4952.html" rel="external">"Hypertrophic cardiomyopathy: Risk stratification for sudden cardiac death"</a>.)</p><p></p><p>The clinical manifestations, diagnosis, prognosis, and pathophysiology of HCM are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4916.html" rel="external">"Hypertrophic cardiomyopathy: Natural history and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation"</a>.)</p><p></p><p class="headingAnchor" id="H3461056331"><span class="h1">IDENTIFICATION OF OUTFLOW OBSTRUCTION</span><span class="headingEndMark"> — </span>The definition of left ventricular outflow tract obstruction and its management are described separately. (See  <a class="medical medical_review" href="/d/html/4920.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients with outflow tract obstruction", section on 'Determining the severity of obstruction'</a>.)</p><p class="headingAnchor" id="H691739800"><span class="h1">EVALUATION OF SYMPTOMS</span></p><p class="headingAnchor" id="H1656574686"><span class="h2">Etiology of symptoms</span><span class="headingEndMark"> — </span>Given the importance of left ventricular outflow tract (LVOT) obstruction as the predominant mechanism of limiting symptoms in patients with HCM, it is imperative that all patients with HCM undergo assessment for obstruction. Assessment for obstruction typically includes resting echocardiography, and, if obstruction is absent or &lt;50 mmHG at rest, patients should undergo provocation, with exercise echocardiography preferred. The assessment for obstruction and the approach to treatment of symptoms caused by LVOT obstruction are discussed separately. (See  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'LVOT obstruction'</a> and  <a class="medical medical_review" href="/d/html/4920.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients with outflow tract obstruction"</a>.)</p><p>In patients without LVOT obstruction at rest or with provocation (ie, truly nonobstructive HCM), symptoms of dyspnea, fatigue, chest pain, palpitation, and syncope may be caused by any combination of diastolic dysfunction, mitral regurgitation, "small vessel" ischemia, arrhythmias, or noncardiac diseases including abnormal peripheral vascular responses [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H359024727"><span class="h2">Chest pain</span><span class="headingEndMark"> — </span>In patients with nonobstructive HCM who have new-onset or worsening chest pain, the evaluation is primarily focused on assessing for signs or symptoms that suggest the presence of epicardial coronary artery disease (CAD). Thus, the initial evaluation of chest pain in patients with nonobstructive HCM includes the following elements:</p><p class="bulletIndent1"><span class="glyph">●</span>History focused on the risk factors, time course, duration, location, and other characteristics of chest pain (eg, exacerbating factors, relieving factors). (See  <a class="medical medical_review" href="/d/html/6832.html" rel="external">"Outpatient evaluation of the adult with chest pain", section on 'History and physical examination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination to identify new murmurs or signs of cardiac decompensation such as heart failure (HF). (See  <a class="medical medical_review" href="/d/html/1078.html" rel="external">"Auscultation of cardiac murmurs in adults"</a> and  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults", section on 'Physical examination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram (ECG) or ambulatory monitoring to identify evidence of ischemia, prior myocardial infarction, or any abnormal rhythms associated with chest discomfort (eg, premature ventricular depolarizations).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Repeat echocardiography with provocation to assess for changes in cardiac structure or function, especially latent LVOT obstruction.</p><p></p><p>After an initial evaluation, patients with signs or symptoms of obstructive CAD should be appropriately tested. In patients with HCM, the choice of test for obstructive CAD is similar to that in patients without HCM. However, given the relatively high false positive rates with exercise nuclear stress testing, it is reasonable to obtain coronary computed tomographic angiography (CCTA) as the initial test for CAD; CCTA has a high negative predictive value. (See  <a class="medical medical_review" href="/d/html/1534.html" rel="external">"Stress testing for the diagnosis of obstructive coronary heart disease"</a> and  <a class="medical medical_review" href="/d/html/129395.html" rel="external">"Clinical use of coronary computed tomographic angiography", section on 'Patients with stable symptoms'</a>.)</p><p>In patients with HCM who have no evidence of macrovascular (ie, epicardial) CAD (eg, normal coronary angiogram or CCTA) or who are refractory to appropriate therapies for chest pain, microvascular or small vessel ischemia is likely present. In most patients with suspected microvascular disease, we proceed with therapy for chest pain and only obtain additional testing (eg, positron emission tomography with coronary flow reserve testing) in select individuals in whom the diagnosis is unclear.</p><p class="headingAnchor" id="H93218580"><span class="h2">Dyspnea and exertional fatigue</span><span class="headingEndMark"> — </span>There are many causes of dyspnea and exertional fatigue in patients with nonobstructive HCM. The most common causes include:</p><p class="bulletIndent1"><span class="glyph">●</span>Ischemia</p><p class="bulletIndent1"><span class="glyph">●</span>Diastolic or systolic LV dysfunction with attendant HF</p><p class="bulletIndent1"><span class="glyph">●</span>Permanent or paroxysmal atrial arrhythmias</p><p class="bulletIndent1"><span class="glyph">●</span>Noncardiac causes (eg, obesity)</p><p></p><p>In patients with nonobstructive HCM, the evaluation for the cause of dyspnea and fatigue includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>History focused on the nature and severity of symptoms. (See  <a class="medical medical_review" href="/d/html/6832.html" rel="external">"Outpatient evaluation of the adult with chest pain", section on 'History and physical examination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination focused on identifying signs of HF. (See  <a class="medical medical_review" href="/d/html/1078.html" rel="external">"Auscultation of cardiac murmurs in adults"</a> and  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults", section on 'Physical examination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory studies that include serum creatinine and B-type natriuretic peptide. (See  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults", section on 'Initial blood tests'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chest radiography to assess for pulmonary edema or intrinsic lung disease. (See  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults", section on 'Chest radiograph'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echocardiography to assess for changes in cardiac structure and function that includes an assessment for the presence of newly identified LVOT obstruction. (See  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'Echocardiography'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Invasive study with right heart catheterization to directly measure LV filling pressures and cardiac output may be helpful in assessing etiology of symptoms in select patients with HCM in whom the cause of symptoms is uncertain after conventional testing.</p><p></p><p>In patients with signs or symptoms of ischemia, we obtain an appropriate evaluation for ischemia, as described above. (See <a class="local">'Chest pain'</a> above.)</p><p>In patients without a clear cardiac cause for dyspnea or fatigue, other causes of these symptoms should be investigated. (See  <a class="medical medical_review" href="/d/html/1436.html" rel="external">"Approach to the patient with dyspnea"</a> and  <a class="medical medical_review" href="/d/html/2783.html" rel="external">"Approach to the adult patient with fatigue"</a>.)</p><p class="headingAnchor" id="H3672587516"><span class="h2">Palpitations, syncope, or other symptoms of arrhythmias</span><span class="headingEndMark"> — </span>In patients with nonobstructive HCM and syncope, the causes of syncope include atrial fibrillation and, less commonly, ventricular arrhythmias, conduction system disease (eg, atrioventricular block), and neurocardiogenic or vasovagal mechanisms.</p><p>For patients with nonobstructive HCM and documented or suspected syncope, the evaluation includes:</p><p class="bulletIndent1"><span class="glyph">●</span>History focused on the circumstances leading to the event, prodrome, presence or absence of loss of consciousness, and immediate effects of the episode (eg, seizure-like activity, postsyncopal symptoms). (See  <a class="medical medical_review" href="/d/html/969.html" rel="external">"Syncope in adults: Clinical manifestations and initial diagnostic evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination with a focus on any changes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum electrolytes including potassium and magnesium levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ECG.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Repeat echocardiography to assess for changes in cardiac structure and function that includes assessment for the presence of newly identified LVOT obstruction.</p><p></p><p>If a rhythm was not recorded during the event, we recommend an ambulatory patch monitor or mobile cardiac outpatient telemetry for most patients. (See  <a class="medical medical_review" href="/d/html/958.html" rel="external">"Ambulatory ECG monitoring", section on 'Patch monitor'</a> and  <a class="medical medical_review" href="/d/html/958.html" rel="external">"Ambulatory ECG monitoring", section on 'Mobile cardiac outpatient telemetry (MCOT)'</a>.)</p><p>In rare patients in whom the cause of syncope cannot be established with routine testing, additional testing may be required. (See  <a class="medical medical_review" href="/d/html/1016.html" rel="external">"Upright tilt table testing in the evaluation of syncope"</a>.)</p><p class="headingAnchor" id="H2102756948"><span class="h1">TREATMENT FOR SYMPTOMS</span></p><p class="headingAnchor" id="H2595503865"><span class="h2">Chest discomfort</span><span class="headingEndMark"> — </span>In patients with nonobstructive HCM who have chest discomfort without evidence of obstructive coronary artery disease (CAD), we suggest initial treatment with a nondihydropyridine calcium channel blocker (eg, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> or <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>) or a beta blocker (eg, <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> succinate) rather than with other agents (eg, nitrates, <a class="drug drug_general" data-topicid="10262" href="/d/drug information/10262.html" rel="external">ranolazine</a>). The typical approach to use of nondihydropyridine calcium channel blocker or beta blocker therapy is to start with a low dose and increase until control of chest pain is satisfactory. In our experience, control of chest pain typically requires a relatively high dose (eg, 360 mg of sustained release verapamil per day) of these agents.</p><p>In patients who cannot take a calcium channel blocker or a beta blocker or whose symptoms are not controlled with one of these drugs, we suggest a trial of <a class="drug drug_general" data-topicid="10262" href="/d/drug information/10262.html" rel="external">ranolazine</a> rather than nitrates.</p><p>There are limited data to guide the treatment of chest pain in patients with HCM. The approach above reflects our experience. In one trial that compared <a class="drug drug_general" data-topicid="10262" href="/d/drug information/10262.html" rel="external">ranolazine</a> with placebo, ranolazine had no clear effect on chest pain scores or quality of life [<a href="#rid2">2</a>]. Regardless of this result, we consider ranolazine in patients who have not responded to other treatment options.</p><p class="headingAnchor" id="H3710895687"><span class="h2">Heart failure with systolic dysfunction</span><span class="headingEndMark"> — </span>For patients with nonobstructive HCM, typical New York Heart Association class II to IV HF symptoms, and evidence of LV systolic dysfunction (eg, LV ejection fraction [LVEF] &lt;50 percent), the approach to the treatment of HF is similar to the approach used for patients who have other causes HF with reduced LVEF. (See  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p>Evidence on the optimal approach to such patients is limited, but most experts treat these patients using the standard approach to patients with HF due to systolic dysfunction [<a href="#rid3">3,4</a>]. In addition, patients who have progressive and severe HF symptoms despite therapy may be candidates for heart transplantation or, less commonly, mechanical circulatory support [<a href="#rid3">3-6</a>].</p><p class="headingAnchor" id="H1254936192"><span class="h2">Heart failure with normal ejection fraction</span><span class="headingEndMark"> — </span>For nonobstructive HCM patients with symptoms of HF (eg, edema, congestion, orthopnea) and LVEF ≥50 percent, treatment consists of appropriate diuresis and management of conditions that may contribute to HF exacerbations. In some patients with HCM who have signs of restriction and LVEF &gt;50 percent, management is more similar to that in patients with restrictive cardiomyopathy (eg, diuretics, evaluation for transplantation) than it is to that in patients with HF with preserved ejection fraction. The management of patients with restrictive cardiomyopathy is discussed separately. (See  <a class="medical medical_review" href="/d/html/4918.html" rel="external">"Restrictive cardiomyopathies", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H2286530996"><span class="h2">Symptomatic arrhythmias</span><span class="headingEndMark"> — </span>Patients with HCM who have palpitations, presyncope, or syncope should be managed based on the most likely cause of their symptoms. The management of these rhythms in patients with HCM is covered separately. (See  <a class="medical medical_review" href="/d/html/4926.html" rel="external">"Hypertrophic cardiomyopathy in adults: Supraventricular tachycardias including atrial fibrillation"</a> and  <a class="medical medical_review" href="/d/html/119625.html" rel="external">"Hypertrophic cardiomyopathy: Management of ventricular arrhythmias and sudden cardiac death risk"</a>.)</p><p class="headingAnchor" id="H2756305250"><span class="h2">Heart failure with extensive apical hypertrophy</span><span class="headingEndMark"> — </span>In highly selected patients with nonobstructive HCM in whom hypertrophy predominantly affects the mid to distal portion of the LV cavity and who have severe exercise limitation despite medical therapy, apical myectomy at an experienced center may be an option for treatment. Ideal candidates for apical myectomy typically have a small LV cavity size (LV end-diastolic volume &lt;50 mL/m<sup>2</sup> and LV stroke volume &lt;30 mL/m<sup>2</sup>). In such patients, apical myectomy can increase cavity size, which may increase stroke volume and improve HF symptoms [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H1719092630"><span class="h2">Refractory heart failure symptoms</span><span class="headingEndMark"> — </span>Similar to other patients with advanced HF, transplantation and, rarely, mechanical circulatory support may be an option for some patients with HCM. The approach to these therapies is discussed separately. (See  <a class="medical medical_review" href="/d/html/3528.html" rel="external">"Heart transplantation in adults: Indications and contraindications"</a> and  <a class="medical medical_review" href="/d/html/3459.html" rel="external">"Treatment of advanced heart failure with a durable mechanical circulatory support device"</a>.)</p><p class="headingAnchor" id="H2758929884"><span class="h1">MANAGEMENT OF ASYMPTOMATIC PATIENTS</span></p><p class="headingAnchor" id="H788317171"><span class="h2">Observation only</span><span class="headingEndMark"> — </span>Patients with HCM who are asymptomatic can be managed with close clinical observation and do not require pharmacologic therapy. In trials of asymptomatic patients, prophylactic treatment does not appear to alter the natural history of HCM. Major professional societies do not recommend routine pharmacologic therapy for asymptomatic patients [<a href="#rid4">4,8</a>].</p><p>One trial in asymptomatic or mildly symptomatic patients showed no effect on surrogate outcomes:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial of 133 patients with HCM who had minimal or no symptoms (94 percent New York Heart Association class 1 or 2), patients were randomized to <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">losartan</a> 100 mg daily or placebo (in addition to standard HCM therapy). After 12 months of observation, LV systolic function, left atrial volume, and exercise capacity were similar in the two treatment groups [<a href="#rid9">9</a>]. While apparently safe in patients without LVOT obstruction, losartan had no impact on HCM disease progression and should not be routinely used in the treatment of patients with obstructive HCM. (See  <a class="medical medical_review" href="/d/html/4920.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients with outflow tract obstruction", section on 'Therapies to avoid'</a>.)</p><p></p><p class="headingAnchor" id="H1160588979"><span class="h2">Treatment for sudden death</span><span class="headingEndMark"> — </span>Some asymptomatic patients with HCM have clinical or morphologic features that increase the risk of sudden death. The approach to sudden death prevention in patients with HCM is discussed separately. (See  <a class="medical medical_review" href="/d/html/4952.html" rel="external">"Hypertrophic cardiomyopathy: Risk stratification for sudden cardiac death"</a> and  <a class="medical medical_review" href="/d/html/119625.html" rel="external">"Hypertrophic cardiomyopathy: Management of ventricular arrhythmias and sudden cardiac death risk"</a>.)</p><p class="headingAnchor" id="H3898521524"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115416.html" rel="external">"Society guideline links: Cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15753.html" rel="external">"Patient education: Hypertrophic cardiomyopathy in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/3445.html" rel="external">"Patient education: Hypertrophic cardiomyopathy (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of symptoms</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Etiology of symptoms</strong> – In patients with nonobstructive hypertrophic cardiomyopathy (HCM), the symptoms of dyspnea, fatigue, chest pain, palpitation, and syncope may be caused by any combination of diastolic dysfunction, mitral regurgitation, "small vessel" ischemia, arrhythmias, or noncardiac diseases including abnormal peripheral vascular responses. (See <a class="local">'Etiology of symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chest pain</strong> – In patients with nonobstructive HCM who have new-onset or worsening chest pain, the evaluation is primarily focused on assessing for signs or symptoms that suggest the presence of epicardial coronary artery disease (CAD). (See <a class="local">'Chest pain'</a> above.)</p><p></p><p class="bulletIndent2">In patients with HCM, the choice of test for obstructive CAD is similar to patients without HCM and is discussed separately. (See  <a class="medical medical_review" href="/d/html/1534.html" rel="external">"Stress testing for the diagnosis of obstructive coronary heart disease"</a> and  <a class="medical medical_review" href="/d/html/129395.html" rel="external">"Clinical use of coronary computed tomographic angiography", section on 'Patients with stable symptoms'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dyspnea and exertional fatigue</strong> – There are many causes of dyspnea and exertional fatigue in patients with nonobstructive HCM. The most common causes include ischemia, heart failure (HF), arrhythmias, and noncardiac causes (eg, obesity). (See <a class="local">'Dyspnea and exertional fatigue'</a> above.)</p><p></p><p class="bulletIndent2">In patients without a clear cardiac cause for dyspnea or fatigue, other causes of these symptoms should be investigated. (See  <a class="medical medical_review" href="/d/html/1436.html" rel="external">"Approach to the patient with dyspnea"</a> and  <a class="medical medical_review" href="/d/html/2783.html" rel="external">"Approach to the adult patient with fatigue"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Palpitations, syncope, or other symptoms </strong>– In patients with nonobstructive HCM and syncope, the causes of syncope include ventricular arrhythmias, high-level conduction disease, and neurocardiogenic or vasovagal mechanisms. If a rhythm was not recorded during the event, we recommend an ambulatory patch monitor or mobile cardiac outpatient telemetry for most patients. (See  <a class="medical medical_review" href="/d/html/958.html" rel="external">"Ambulatory ECG monitoring", section on 'Our approach to choosing an ambulatory ECG monitoring strategy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatments for symptoms or syndromes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chest discomfort</strong> – In patients with nonobstructive HCM who have chest discomfort without evidence of obstructive CAD, we suggest initial treatment with <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> or <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> rather than with other negative inotropes or other agents typically used to treat chest pain (eg, nitrates, <a class="drug drug_general" data-topicid="10262" href="/d/drug information/10262.html" rel="external">ranolazine</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">In patients who cannot take <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> or <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> or whose symptoms are not controlled with one of these drugs, we suggest a trial of beta blockers or <a class="drug drug_general" data-topicid="10262" href="/d/drug information/10262.html" rel="external">ranolazine</a> rather than nitrates (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Chest discomfort'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Heart failure with systolic dysfunction</strong> – For nonobstructive HCM patients with typical New York Heart Association class II to IV HF symptoms and evidence of left ventricular (LV) systolic dysfunction (eg, LV ejection fraction [LVEF] &lt;50 percent), the approach to the treatment of HF is similar to the approach used for patients who have other causes HF with reduced LVEF. (See <a class="local">'Heart failure with systolic dysfunction'</a> above and  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Heart failure with normal ejection fraction</strong> – For patients with nonobstructive HCM, symptoms of HF (eg, edema, congestion, orthopnea), and LVEF ≥50 percent, treatment consists of appropriate diuresis and management of conditions that may contribute to HF exacerbations. The treatment of these patients is similar to patients with restrictive cardiomyopathy. (See  <a class="medical medical_review" href="/d/html/4918.html" rel="external">"Restrictive cardiomyopathies", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Symptomatic arrhythmias</strong> – Patients with HCM who have palpitations, presyncope, or syncope should be managed based on the most likely cause of their symptoms. The management of these rhythms in patients with HCM is covered separately. (See  <a class="medical medical_review" href="/d/html/4926.html" rel="external">"Hypertrophic cardiomyopathy in adults: Supraventricular tachycardias including atrial fibrillation"</a> and  <a class="medical medical_review" href="/d/html/119625.html" rel="external">"Hypertrophic cardiomyopathy: Management of ventricular arrhythmias and sudden cardiac death risk"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe heart failure symptoms</strong> – Similar to other patients with advanced HF, transplantation and, rarely, mechanical circulatory support may be an option for some patients with HCM. The approach to these therapies is discussed separately. (See  <a class="medical medical_review" href="/d/html/3528.html" rel="external">"Heart transplantation in adults: Indications and contraindications"</a> and  <a class="medical medical_review" href="/d/html/3459.html" rel="external">"Treatment of advanced heart failure with a durable mechanical circulatory support device"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of asymptomatic patients</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pharmacologic treatment </strong>– Patients with HCM who are asymptomatic can be managed with close clinical observation and do not require pharmacologic therapy. (See <a class="local">'Observation only'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment to prevent sudden death</strong> – Some asymptomatic patients with HCM have clinical or morphologic features that increase the risk of sudden death. The approach to sudden death prevention in patients with HCM is discussed separately. (See  <a class="medical medical_review" href="/d/html/4952.html" rel="external">"Hypertrophic cardiomyopathy: Risk stratification for sudden cardiac death"</a> and  <a class="medical medical_review" href="/d/html/119625.html" rel="external">"Hypertrophic cardiomyopathy: Management of ventricular arrhythmias and sudden cardiac death risk"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336:775.</a></li><li><a class="nounderline abstract_t">Olivotto I, Camici PG, Merlini PA, et al. Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study. Circ Heart Fail 2018; 11:e004124.</a></li><li><a class="nounderline abstract_t">Spirito P, Autore C. Management of hypertrophic cardiomyopathy. BMJ 2006; 332:1251.</a></li><li><a class="nounderline abstract_t">Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2761.</a></li><li><a class="nounderline abstract_t">Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002; 287:1308.</a></li><li><a class="nounderline abstract_t">Shirani J, Maron BJ, Cannon RO 3rd, et al. Clinicopathologic features of hypertrophic cardiomyopathy managed by cardiac transplantation. Am J Cardiol 1993; 72:434.</a></li><li><a class="nounderline abstract_t">Nguyen A, Schaff HV, Nishimura RA, et al. Apical myectomy for patients with hypertrophic cardiomyopathy and advanced heart failure. J Thorac Cardiovasc Surg 2020; 159:145.</a></li><li><a class="nounderline abstract_t">Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020; 142:e558.</a></li><li><a class="nounderline abstract_t">Axelsson A, Iversen K, Vejlstrup N, et al. Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial. Heart 2016; 102:285.</a></li></ol></div><div id="topicVersionRevision">Topic 4950 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9052657" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The management of hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29321131" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16735335" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Management of hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22068435" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11886323" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hypertrophic cardiomyopathy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8352187" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinicopathologic features of hypertrophic cardiomyopathy managed by cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31053431" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Apical myectomy for patients with hypertrophic cardiomyopathy and advanced heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33215931" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26661322" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
